- Experience of the usage of nabumetone in oncogynecologic patients
Experience of the usage of nabumetone in oncogynecologic patients
HEALTH OF WOMAN. 2017.3(119):118–122; doi 10.15574/HW.2017.119.118
Kartashov S. M., Oleshko E. M.
Kharkiv medical Academy of postgraduate education
Objective: to study the effect of nabumetone in oncogynecologic patients in the postoperative period.
Materials and methods. There were examined 98 patients of 40-78 years old, who were divided into two groups: the main group – 58 patients, of which 37 – patients with endometrial cancer I-III and 21 – with ovarian cancer of II-IV stage (FIGO); The comparison group included 40 patients (17 and 23 patients respectively). All patients underwent surgical treatment. In the postoperative period, were used NSAIDs – nabumeton. Before the operation and on the 10th day of the postoperative period, the following parameters were studied: a clinical blood test, TNF-a, ceruloplasmin, diene conjugates (DC), malonic dialdehyde (MDA), antioxidant activity (AOA). The content of TNF-a, in the blood serum was determined by radioimmunological, and DC, MDA, AOA by biochemical method.
Results. Established: the content of the leukocyte formula before the start of treatment in the compared groups did not reveal any significant differences. After surgical intervention, both groups showed an increase in the absolute values of all leukocyte fractions. The level of ceruloplasmin in the patients of the comparison group increased significantly in the postoperative period, and in the main group the parameters of ceruloplasmin did not differ significantly. The level of TNF-a in the pre- and postoperative period in the compared groups did not differ. On the 10th day of the postoperative period, it significantly increased in the comparison group, and when nabumetone was used during the postoperative period, the level of TNF-a did not increase. The initial indicators characterizing the processes of LPO and AOA in both groups did not differ significantly. Assessing the dynamics of indicators before and after the operation, it was noted that in patients in the blood, the level of DC in both the baseline and in the comparison group increased. The use of nabumethon led to a slight increase in DC. The maintenance MDA in the postoperative period has increased in both groups, however it is unreliable in comparison with parameters before surgical intervention. In the comparison group, after the treatment, the antioxidant defense was reliably reduced. In the main group, the use of nabumetone contributed to a smaller decrease in AOA. The use of nabumeton allowed abandoning of narcotic analgesics in earlier periods of the postoperative period.
Conclusion. Use of nabumeton in the postoperative period allows to reduce the pain syndrome, the number of inflammatory complications; contributes to the normalization of LPO processes, inhibits the inhibition of the antioxidant system, which contributes to the reduction of endogenous intoxication and improves the results of treatment of oncogynecologic patients.
Key words: nabumeton, oncogynecologic patients, anti-inflammatory action, tumor necrosis factor, ceruloplasmin, diene conjugates, malanialdehyde, antioxidant activity.
1. Osipova NA. 2006. Novyie tendentsii v taktike farmakoterapii hronicheskoy rakovoy boli. Bol. 2(11):38–44.
2. Reshetnyak VK, Kukushkin ML. 2001. Bol: fiziologicheskie i patofiziologicheskie aspektyi. V Kn.: Aktualnyie problemyi patofiziologii (izbrannyie lektsii). Pod red. BB Moroza. M, Meditsina:354–389.
3. Osipova NA, Abuzarova GR. 2006. Neyropaticheskaya bol v onkologii: sovremennaya farmakoterapiya. M:22.
4. Nasonov EL. 2003. Primenenie nesteroidnyih protivovospalitelnyih preparatov v meditsine v nachale 21 veka. Russkiy meditsinskiy zhurnal 11(7):375–378.
5. Nesteroidnyie protivovospalitelnyie sredstva: metodicheskoe posobie. Pod. red. LS Strachunskiy, SN Kozlov. Smolensk. 2006.
6. Perez-Ezquerra PR, Sanchez-Morillas L, Laguna Martinez JJ et al. 2013, Jul. Hypersensitivity to nabumetone: cross reactivity with naproxen. Ann Allergy Asthma Immunol. 111(1):74–5. https://doi.org/10.1016/j.anai.2013.05.006; PMid:23806470
7. Setoguchi N, Takamura N, Fujita K et al. 2013, Mar. A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. Biopharmaceutics & Drug Disposition. 34(2):125–36. https://doi.org/10.1002/bdd.1829; PMid:23225308
8. Hung SC, Liao KF, Hung HC et al. 2016, May-Jun. Nabumetone use and risk of acute pancreatitis in a case-control study. Pancreatology 16(3):353–7. https://doi.org/10.1016/j.pan.2016.03.003; PMid:27029853